Why adverse outcome pathways need to be FAIR
Adverse outcome pathways (AOPs) provide evidence for demonstrating and assessing causality between measurable toxicological mechanisms and human or environmental adverse effects. AOPs have gained increasing attention over the past decade and are believed to provide the necessary steppingstone for more effective risk assessment of chemicals and materials and moving beyond the need for animal testing. However, as with all types of data and knowledge today, AOPs need to be reusable by machines, i.e., machine-actionable, in order to reach their full impact potential. Machine-actionability is supported by the FAIR principles, which guide findability, accessibility, interoperability, and reusability of data and knowledge. Here, we describe why AOPs need to be FAIR and touch on aspects such as the improved visibility and the increased trust that FAIRification of AOPs provides.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
ALTEX - 41(2024), 1 vom: 09. Jan., Seite 50-56 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wittwehr, Clemens [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse outcome pathways (AOPs) |
|---|
| Anmerkungen: |
Date Completed 10.01.2024 Date Revised 10.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.14573/altex.2307131 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36028518X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36028518X | ||
| 003 | DE-627 | ||
| 005 | 20240114233340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14573/altex.2307131 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1255.xml |
| 035 | |a (DE-627)NLM36028518X | ||
| 035 | |a (NLM)37528748 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wittwehr, Clemens |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Why adverse outcome pathways need to be FAIR |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.01.2024 | ||
| 500 | |a Date Revised 10.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Adverse outcome pathways (AOPs) provide evidence for demonstrating and assessing causality between measurable toxicological mechanisms and human or environmental adverse effects. AOPs have gained increasing attention over the past decade and are believed to provide the necessary steppingstone for more effective risk assessment of chemicals and materials and moving beyond the need for animal testing. However, as with all types of data and knowledge today, AOPs need to be reusable by machines, i.e., machine-actionable, in order to reach their full impact potential. Machine-actionability is supported by the FAIR principles, which guide findability, accessibility, interoperability, and reusability of data and knowledge. Here, we describe why AOPs need to be FAIR and touch on aspects such as the improved visibility and the increased trust that FAIRification of AOPs provides | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a FAIR data | |
| 650 | 4 | |a adverse outcome pathways (AOPs) | |
| 650 | 4 | |a machine-actionability | |
| 650 | 4 | |a trust | |
| 650 | 4 | |a visibility | |
| 700 | 1 | |a Clerbaux, Laure-Alix |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Angrish, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Mortensen, Holly |e verfasserin |4 aut | |
| 700 | 1 | |a Carusi, Annamaria |e verfasserin |4 aut | |
| 700 | 1 | |a Gromelski, Maciej |e verfasserin |4 aut | |
| 700 | 1 | |a Lekka, Eftychia |e verfasserin |4 aut | |
| 700 | 1 | |a Virvilis, Vassilis |e verfasserin |4 aut | |
| 700 | 1 | |a Martens, Marvin |e verfasserin |4 aut | |
| 700 | 1 | |a Bonino da Silva Santos, Luiz Olavo |e verfasserin |4 aut | |
| 700 | 1 | |a Nymark, Penny |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ALTEX |d 1988 |g 41(2024), 1 vom: 09. Jan., Seite 50-56 |w (DE-627)NLM110013646 |x 1868-8551 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g number:1 |g day:09 |g month:01 |g pages:50-56 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.14573/altex.2307131 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2024 |e 1 |b 09 |c 01 |h 50-56 | ||